Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.

After a median of 3.9 years of follow-up, a strong trend towards increased 5-year DFS was noted with concurrent trastuzumab and paclitaxel relative to sequential administration (HR 0.77, 99.9 % CI 0.53−1.11; p = 0.0216), but the p value did not cross the prespecified O’Brien–Fleming boundary for the interim analysis [ 17 ].

also in 5,725 other papers